Continue Reading Below
According to data fromS&P Global Market Intelligence,shares of Vertex Pharmaceuticals (NASDAQ: VRTX), a large-cap biotech focused on rare diseases, rose by 5% in February.
It was a quiet month for Vertex. The company didn't issue a single press release or attend an investor conference during the month that could help to justify the move. There weren't any analyst upgrades during the period, either.
Image source: Getty Images.
So why did shares rally? The likely reason is that the company simply benefited from thegeneral rally in the biotechnology sector. The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB)-- an ETF that owns a number of large-cap biotechnology stocks -- gained 6% during the month. That move closely matches Vertex's rise.
Continue Reading Below
It is also worth pointing out that Vertex's stock jumped by a strong 17% in January. That hints that the stock could have caught the attention of traders who buy based on momentum, which could have also contributed to the gains.
2017 promises to be a transformative year for Vertex. Using the midpoint of its guidance range, management expects the company to grow its top-line by more than 13%. Better yet, non-GAAP spending on R&D and SG&A are only expected to grow by5%. If the company can hit those figures then it should be able toproduce a nice profit for the full year.
Beyond the financials, investors can also look forward to a number of clinical updates. The company is expecting Phase 3 data from its tezacaftor/ivacafrot product candidate in the first half of this year. Phase 2 data readouts are also expected from VX-440 and VX-152. Both of these drugs promise to be next-generation drugs for treating Cystic Fibrosis and both already have fast-track designation from the FDA.
With profits on the way and an advancing pipeline, Vertex is providing investors with plenty of reasons for investors to feel bullish about the year ahead. While the company's shares are richly priced, this might be a high-growth biotech stock that is worth paying a premium to own.
10 stocks we like better than Vertex Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Vertex Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of February 6, 2017